April 28, 2020 - "Resilient business driving continued growth in challenging times"
Today the company announces the US launch of its scientifically proven digital therapies deprexis® and vorvida® has been initiated. The decision to accelerate the launch of the digital offering, also incl. OXD01, is based on the patient need for access to low-risk clinically-validated digital health devices during the ongoing COVID-19 pandemic and the recent FDA “Enforcement Policy” providing a fast pathway to market. The accelerated launch will increase investments and OPEX FY 2020 expects to be in the range of SEK 780-800 m.
JUNE 30, 2020 - Preliminary results for OX125 indicate extensive and rapid absorption across all formulations as well as good tolerability, supporting the viability of OX125 as a rescue medication for opioid overdose. OX125 could be an important addition to OX124 and the results underline the applicability of Orexo’s novel intranasal drug delivery platform.
Our colleague Geri Lynn Utter is, mildly spoken, the right person at the right place. As a child of parents who suffered from drug addiction, she, against all odds, became a doctor of psychology. A moving story depicted in her first book ”Mainlining Philly”. Today, in her role as Medical Science Liaison at Orexo, Geri plays a key role in raising awareness around addiction and mental health issues.
An urgent call to increase funding and solutions for treatment of mental health illness in the wake of the… https://t.co/lPmUiGvY8q
NEWS Post 2(2) In addition to the US launch of two digital therapeutics we are also accelerating the launch of our… https://t.co/e23xzdetkS
NEWS post 1(2) We are delighted to announce the US launch of two scientifically proven digital therapeutics for the… https://t.co/M4tuzdHJmN